| Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care (NCT03420430) | Genelux Corporation | |
| Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) (NCT01945619) | Baylor College of Medicine | |
| 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors (NCT01980732) | Andrei Iagaru | |
| A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL (NCT04194190) | National Institutes of Health Clinical Center (CC) | |
| HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option (NCT02934282) | Mauricio Lynn | |
| Individual Patient Expanded Access IND for the Treatment of Stroke (NCT04907188) | Hope Biosciences Research Foundation | |
| Managed Access Programs for PKC412, Midostaurin (NCT05219266) | Novartis Pharmaceuticals | |
| Expanded Access to Fosigotifator (NCT06594016) | AbbVie | |
| Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI) (NCT04173013) | Impatients N.V. trading as myTomorrows | |
| An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas (NCT03460782) | Center Trials & Treatment | |
| Percutaneous Endoscopic Tracheal Plug/Unplug for CDH (Congenital Diaphragmatic Hernia) (NCT00768703) | University of California, San Francisco | |
| Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) (NCT04456439) | Mesoblast International Sàrl | |
| Compassionate Use of Stiripentol in Dravet Syndrome (NCT01835314) | University of Colorado, Denver | |
| Canavan-Single Patient IND (NCT05317780) | University of Florida | |
| An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine (NCT03934086) | Pfizer | |
| Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil (NCT00866983) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma (NCT06439849) | Petrov, Andrey | |
| Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer (NCT03424473) | Seagen Inc. | |
| A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation (NCT00511771) | Novartis | |
| Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia (NCT04597242) | ContraFect | |
| B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure (NCT01049633) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients (NCT02473497) | Pfizer | |
| 18F-Floretyrosine Expanded Access Program (NCT06743100) | Telix Pharmaceuticals (Innovations) Pty Limited | |
| AZD9291 US Expanded Access Program (NCT02451852) | AstraZeneca | |
| Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy (NCT00852345) | Kaiser Permanente | |
| Tecovirimat Intravenous Treatment for Orthopox Virus Exposure (NCT05380752) | U.S. Army Medical Research and Development Command | |
| Compassionate Use for Subcutaneous (SC) Belimumab (NCT03125486) | GlaxoSmithKline | |
| Expanded Access for ACE-011 (NCT03724227) | Celgene | |
| Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) (NCT03493152) | The University of Texas Health Science Center at San Antonio | |
| Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 (NCT04358211) | Nakhle Saba, MD | |
| Nilotinib, for Patients With CML-CP or CML-AP (NCT04518644) | Novartis Pharmaceuticals | |
| HIV-discordant Couple Intrauterine Insemination (NCT00975546) | University of Missouri-Columbia | |
| Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) (NCT01432483) | Eisai Inc. | |
| Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD) (NCT00826046) | Mesoblast, Inc. | |
| Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients (NCT04420988) | Rutgers, The State University of New Jersey | |
| Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS (NCT04657458) | Direct Biologics, LLC | |
| Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia (NCT04636554) | Adaptive Phage Therapeutics, Inc. | |
| SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 (NCT04355494) | Alexion Pharmaceuticals, Inc. | |
| Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma (NCT03029481) | Jonsson Comprehensive Cancer Center | |
| An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease (NCT03362736) | Janssen Research & Development, LLC | |
| Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy (NCT03532516) | UCB Biopharma SRL | |
| A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous (NCT03265171) | Prometic Biotherapeutics, Inc. | |
| Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer (NCT04087889) | Hope Biosciences LLC | |
| Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors (NCT01260779) | Provectus Biopharmaceuticals, Inc. | |
| Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction (NCT00764543) | University of Texas Southwestern Medical Center | |
| A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial (NCT03642691) | Prometic Biotherapeutics, Inc. | |
| Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA) (NCT03559686) | UCB Biopharma SRL | |
| ACT for CP Individual Patient Expanded Access IND Protocol (NCT03203941) | Charles Cox | |
| Compassionate Use Trial for Unresectable Melanoma With Ipilimumab (NCT00495066) | Bristol-Myers Squibb | |
| Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy (NCT02233257) | University of Minnesota | |
| Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma (NCT02666209) | Dana-Farber Cancer Institute | |
| Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (NCT02142868) | Pfizer | |
| Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy (NCT03433131) | Harmony Biosciences Management, Inc. | |
| Rociletinib (CO-1686) USA Expanded Access Program (NCT02547675) | Clovis Oncology, Inc. | |
| Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors (NCT06238583) | Bayer | |
| COVID-19 Soliris Expanded Access Protocol (NCT04802083) | Alexion Pharmaceuticals, Inc. | |
| Intermediate-Sized Expanded Access Study (NCT05597436) | Seelos Therapeutics, Inc. | |
| Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis (NCT03906344) | Incyte Corporation | |
| Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (NCT01646593) | Bayer | |
| An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer (NCT01130259) | Sanofi | |
| CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD) (NCT03559660) | UCB Biopharma SRL | |
| A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE (NCT00063791) | Millennium Pharmaceuticals, Inc. | |
| 99m-Technetium- Glucosamine in Arthritis (NCT01789151) | University of Sydney | |
| Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection (NCT04544202) | Novartis Pharmaceuticals | |
| Expanded Use of Cannabidiol Oral Solution (NCT03196934) | MultiCare Health System Research Institute | |
| Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis (NCT00508963) | University of California, San Francisco | |
| Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program) (NCT01931085) | University of Colorado, Denver | |
| Ganaxolone Expanded Access Program Compassionate Use (NCT04678479) | Marinus Pharmaceuticals | |
| ARCHIMEDES Compassionate Use Supplement (NCT00660556) | Cerenovus, Part of DePuy Synthes Products, Inc. | |
| Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT03537807) | Biohaven Pharmaceuticals, Inc. | |
| TVI-Brain-1 in Expanded Access Patient (NCT05936216) | TVAX Biomedical | |
| Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (NCT06743776) | Mayo Clinic | |
| IC14 for ALS Patients Expanded Access (NCT04309604) | Implicit Bioscience | |
| Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia (NCT03633604) | Michael Boisen | |
| An Open Label Access Study For Subjects Who Completed A1481156 (NCT01582438) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04705454) | ADC Therapeutics S.A. | |
| Expanded Access to NanoDoce (NCT04060628) | NanOlogy, LLC | |
| Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NCT01309022) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography (NCT02531672) | Memorial Sloan Kettering Cancer Center | |
| A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C (NCT02161939) | Bristol-Myers Squibb | |
| Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03) (NCT03582930) | ONY | |
| Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults (NCT04583007) | Shire | |
| Compassionate Use Re-Infusion of ATLCAR.CD30 (NCT03914885) | UNC Lineberger Comprehensive Cancer Center | |
| Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients (NCT05215288) | Direct Biologics, LLC | |
| Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine (NCT00994916) | David Lacomis, MD | |
| Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma (NCT04453397) | TeneoOne Inc. | |
| Expanded Access to RXDX-105 for Cancers With RET Alterations (NCT03052569) | Hoffmann-La Roche | |
| HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy. (NCT05154851) | Hope Biosciences Research Foundation | |
| Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair (NCT02480777) | W. Dalton Dietrich | |
| Thrombosomes for Expanded Access Use (NCT04619108) | Cellphire Therapeutics, Inc. | |
| Expanded Access Program for CT1812 (Zervimesine) (NCT06961760) | Cognition Therapeutics | |
| Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) (NCT05107193) | Boehringer Ingelheim | |
| An Extended Access Program for Perampanel (NCT01871233) | Eisai Inc. | |
| YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access (NCT01427582) | University of Texas Southwestern Medical Center | |
| An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (NCT02759042) | CytoDyn, Inc. | |
| Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL (NCT05215405) | Kathleen Ludwig | |
| An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options (NCT04739150) | Boehringer Ingelheim | |
| An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer (NCT04578444) | Jazz Pharmaceuticals | |
| EPI-743 for Mitochondrial Respiratory Chain Diseases (NCT01370447) | PTC Therapeutics | |
| Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome (NCT04798066) | Hope Biosciences Research Foundation | |